View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Apr. 30, 2019	Jun. 03, 2019
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Apr. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity's Reporting Status Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,020,815
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Apr. 30, 2019	Oct. 31, 2018
Current Assets:
Cash and cash equivalents	$ 33,706	$ 44,141
Restricted cash		977
Accounts receivable		1,664
Deferred expenses	3,090	2,072
Prepaid expenses and other current assets	1,587	1,611
Total current assets	38,383	50,465
Property and equipment (net of accumulated depreciation)	6,157	6,684
Intangible assets (net of accumulated amortization)	4,951	4,838
Other assets	280	280
Total assets	49,771	62,267
Current liabilities:
Accounts payable	1,568	5,646
Accrued expenses	3,589	6,185
Deferred revenue		4,476
Common stock warrant liability	213	6,517
Other current liabilities	48	48
Total current liabilities	5,418	22,872
Deferred revenue-net of current portion		14,189
Other liabilities	1,183	1,155
Total liabilities	6,601	38,216
Commitments and contingencies - Note 10
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at April 30, 2019 and October 31, 2018 Liquidation preference of $0 at April 30, 2019 and October 31, 2018
Common stock - $0.001 par value; 170,000,000 shares authorized, 8,020,370 and 4,634,189 shares issued and outstanding at April 30, 2019 and October 31, 2018, respectively	8	5
Additional paid-in capital	407,385	391,703
Accumulated deficit	(364,223)	(367,657)
Total stockholders' equity	43,170	24,051
Total liabilities and stockholders' equity	$ 49,771	$ 62,267

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Apr. 30, 2019	Oct. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Series B Preferred stock, shares issued	0	0
Series B Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	8,020,370	4,634,189
Common stock, shares outstanding	8,020,370	4,634,189

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Income Statement [Abstract]
Revenue	$ 1,188	$ 1,747	$ 20,877	$ 3,803
Operating expenses:
Research and development expenses	5,969	10,368	12,675	27,119
General and administrative expenses	3,092	4,932	5,759	10,785
Total operating expenses	9,061	15,300	18,434	37,904
(Loss) income from operations	(7,873)	(13,553)	2,443	(34,101)
Other income (expense):
Interest income, net	113	151	259	291
Net changes in fair value of derivative liabilities	(14)		2,395
Loss on shares issued in settlement of warrants	(1,607)		(1,607)
Other expense	(2)	(6)	(6)	(40)
Net (loss) income before benefit for income taxes	(9,383)	(13,408)	3,484	(33,850)
Income tax expense			50	50
Net (loss) income	$ (9,383)	$ (13,408)	$ 3,434	$ (33,900)
Net (loss) income per common share
Basic	$ (1.59)	$ (4.03)	$ 0.65	$ (11.16)
Diluted	$ (1.59)	$ (4.03)	$ 0.20	$ (11.16)
Weighted average number of common shares outstanding
Basic	5,900,449	3,324,320	5,259,677	3,038,439
Diluted	5,900,449	3,324,320	5,282,772	3,038,439

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
OPERATING ACTIVITIES
Net income (loss)	$ (9,383)	$ (13,408)	$ 3,434	$ (33,900)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock compensation	479	1,225	1,101	4,034
Employee stock purchase plan expense			2
Gain on change in value of warrants	14		(2,395)
Loss on shares issued in settlement of warrants	1,607		1,607
Loss on disposal of property and equipment			2	27
Abandonment of intangible assets	100	200	357	305
Depreciation expense	300	300	571	544
Amortization expense of intangible assets	100	100	193	189
Net accretion of premiums				(4)
Change in operating assets and liabilities:
Accounts receivable			1,664	1,161
Prepaid expenses and other current assets			(994)	(1,765)
Income tax receivable				4,453
Other assets				(162)
Accounts payable and accrued expenses			(6,675)	(2,187)
Deferred revenue			(18,665)	(3,552)
Other liabilities			28	61
Net cash used in operating activities			(19,770)	(30,796)
INVESTING ACTIVITIES
Purchases of short-term investment securities				(12,487)
Proceeds from maturities of short-term investment securities				49,901
Purchase of property and equipment			(54)	(1,277)
Proceeds from disposal of property and equipment			8
Cost of intangible assets			(663)	(990)
Net cash (used in) provided by investing activities			(709)	35,147
FINANCING ACTIVITIES
Net proceeds of issuance of common stock			8,982	21,042
Warrant exercise			68
Proceeds from employee stock purchase plan			17	9
Tax withholdings paid related to net share settlement of equity awards				(40)
Employee tax withholdings paid on equity awards			(13)	(270)
Tax shares sold to pay for employee tax withholdings on equity awards			13	275
Net cash provided by financing activities			9,067	21,016
Net (decrease) increase in cash, cash equivalents and restricted cash			(11,412)	25,367
Cash, cash equivalents and restricted cash at beginning of period			45,118	24,487
Cash, cash equivalents and restricted cash at end of period	33,706	49,854	33,706	49,854
Cash and cash equivalents	33,706	48,877	33,706	48,877
Restricted cash		977		977
Total cash, cash equivalents and restricted cash shown in condensed statements of cash flows	33,706	$ 49,854	33,706	49,854
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes			50	50
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Property and equipment included in accounts payable and accrued expenses				57
Shares issued in settlement of warrants			5,463
Warrant liability reclassified into equity	$ 53		$ 53

Nature of Operations

6 Months Ended

Apr. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations

1. NATURE OF OPERATIONS

Advaxis, Inc. (“Advaxis” or the “Company”) is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Listeria monocytogenes (“Lm”) based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm Technology^TM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;

	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and

	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that LmTechnology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, our product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

Going Concern and Management’s Plans

The Company has not yet commercialized any human products and the products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for an extended period of time. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern within one year after the date the financial statements are issued.

Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its common stock, clinical collaborations, option and warrant exercises, and interest income. From October 2013 through April 2019, the Company raised approximately $275 million in gross proceeds from various public and private offerings of our common stock.

As of April 30, 2019, the Company had approximately $33.7 million in cash and cash equivalents. Management’s plans to mitigate an expected shortfall of capital, to support future operations, include obtaining additional funds through partnerships, strategic or financing investors. The actual amount of cash that it will need to operate is subject to many factors.

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.

Summary of Significant Accounting Policies and Basis of Presentation

6 Months Ended

Apr. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Basis of Presentation

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation/Estimates

The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited condensed balance sheet as of April 30, 2019 has been derived from the Company’s October 31, 2018 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the year ended October 31, 2018 and notes thereto contained in the Company’s annual report on Form 10-K, as filed with the SEC on January 11, 2019.

Reclassification

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.

Concentration of Credit Risk

Financial instruments which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents. All of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality and at times exceed the federally insured limits. The Company had not experienced losses in such accounts and believes it is not exposed to any significant credit risk.

Restricted Cash and Letters of Credit

During July 2017 and January 2018, the Company established two letters of credit with a financial institution as security for the purchase of custom equipment and as security for application fees associated with the Company’s Marketing Authorization Application (“MAA”) in Europe. The letters of credit were collateralized by cash which was unavailable for withdrawal or for usage for general obligations. During the six months ended April 30, 2019, the two letters of credit were terminated and as of April 30, 2019 the Company has no restricted cash balance.

Revenue Recognition

Effective November 1, 2018, the Company adopted ASC Topic 606, Revenue form Contracts with Customers (ASC 606), using the modified retrospective transition method. Under this method, results for reporting periods beginning on November 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605, Revenue Recognition (ASC 605). The Company only applied the modified retrospective transition method to contracts that were not completed as of November 1, 2018, the effective date of adoption for ASC 606. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.

Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

Exclusive Licenses. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a performance obligation is distinct from the other performance obligations, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a performance obligation for its intended purpose without the receipt of the remaining performance obligation, whether the value of the performance obligation is dependent on the unsatisfied performance obligation, whether there are other vendors that could provide the remaining performance obligation, and whether it is separately identifiable from the remaining performance obligation. For licenses that are combined with other performance obligation, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods.

Research and Development Services. The performance obligations under the Company’s collaboration agreements may include research and development services to be performed by the Company on behalf of the partner. Payments or reimbursements resulting from the Company’s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts.

Milestone Payments. At the inception of each arrangement that includes research or development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. An output method is generally to measure progress toward complete satisfaction of a milestone. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Royalties. For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.

Collaborative Arrangements

The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. Amounts that are owed to collaboration partners are recognized as an offset to collaboration revenue as such amounts are incurred by the collaboration partner. For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above under ASC 606.

Recent Accounting Standards

In February 2016, the Financial Accounting Standards Board, (“FASB”), issued Accounting Standards Update, (“ASU”), No. 2016-02, Leases (Topic 842), which establishes a comprehensive new lease accounting model. The new standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than 12 months. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018, with early adoption permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, including a number of optional practical expedients that entities may elect to apply. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, an update which provides another transition method, in addition to the existing modified retrospective transition method, by allowing entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of adopting ASU 2016-02 on the Company’s financial statements.

Recently Adopted Accounting Standards

In May 2014, FASB issued ASU No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. ASU No. 2014-09 superseded the revenue recognition requirements in ASC 605 and created ASC 606 described above. In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. Effective November 1, 2018, the Company adopted ASC 606 using the modified retrospective transition method.

As a result of adopting ASC 606, the Company made reclassifications to the balance sheet and income statement. Net income (loss) was not impacted by the adoption of ASC 606. A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below (in thousands):

	Impact of ASC 606 Adoption on Condensed Balance Sheet as of November 1, 2018
(in thousands)	As reported under ASC 606		Adjustments			Balances without adoption of ASC 606
Accounts receivable	$	1,664	$	1,664		$	-
Prepaid expenses and other current assets	$	1,611	$	(1,664	)	$	3,275

A summary of the amount by which each financial statement line item was affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to the adoption of ASC 606 is set forth in the tables below.

	Impact of ASC 606 Adoption on Condensed Balance Sheet as of April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,587	$	-	$	1,587

	Impact of ASC 606 Adoption on Condensed Statement of Operations for the Three Months Ended April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Revenue	$	1,188	$	73	$	1,115
Research and Development Expenses	$	6,327	$	73	$	6,254

	Impact of ASC 606 Adoption on Condensed Statement of Operations for the Six Months Ended April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Revenue	$	20,877	$	1,960	$	18,917
Research and Development Expenses	$	13,032	$	1,960	$	11,072

	Impact of ASC 606 Adoption on Condensed Statement of Cash Flows for the Six Months Ended April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,587	$	-	$	1,587

The most significant change to the Company’s accounting for revenue as a result of the adoption of ASC 606 relates to its treatment of clinical development payments it receives in its collaboration and licensing agreement with Amgen, Inc. (“Amgen”). Under ASC 605, the Company accounted for the clinical development payments as a reduction of research and development expenses in the statement of operations. Under ASC 606, the Company accounted for the reimbursements for research and development costs as revenue. For further discussion of the adoption of this standard, see Note 9.

In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606” (“ASU 2018-18”). The amendments in ASU 2018-18 make targeted improvements to generally accepted accounting principles (GAAP) for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in Topic 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments should be applied retrospectively to the date of initial application of Topic 606. The Company adopted this guidance effective November 1, 2018 using the modified retrospective approach. There was no impact on the Company’s financial statements.

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718) —Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). The amendments in ASU 2018-07 expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. ASU 2018-07 is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company adopted this guidance effective as of February 1, 2019. There was no impact on the Company’s financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash (ASU No. 2016-18). The amendments in ASU No. 2016-18 require an entity to reconcile and explain the period-over-period change in total cash, cash equivalents and restricted cash within its statements of cash flows. ASU No. 2016-18 was effective for the Company on November 1, 2018. The Company adopted ASU No. 2016-18 effective November 1, 2018 using a full retrospective approach and it did not have a significant impact on its financial statements and related disclosures.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Property and Equipment

6 Months Ended

Apr. 30, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment

3. PROPERTY AND EQUIPMENT

Property and equipment, net consists of the following (in thousands):

	April 30, 2019			October 31, 2018

Leasehold improvements	$	2,335		$	2,321
Laboratory equipment		5,530			5,510
Furniture and fixtures		746			746
Computer equipment		409			409
Construction in progress		17			17
Total property and equipment		9,037			9,003
Accumulated depreciation and amortization		(2,880	)		(2,319	)
Net property and equipment	$	6,157		$	6,684

Depreciation expense for each of the three months ended April 30, 2019 and 2018 was $0.3 million. Depreciation expense for the six months ended April 30, 2019 and 2018 was $0.6 million and $0.5 million, respectively.

Intangible Assets

6 Months Ended

Apr. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. INTANGIBLE ASSETS

Intangible assets, net consist of the following (in thousands):

	April 30, 2019			October 31, 2018

Patents	$	6,240		$	5,970
Licenses		777			777
Software		117			117
Total intangibles		7,134			6,864
Accumulated amortization		(2,183	)		(2,026	)
Intangible assets	$	4,951		$	4,838

The expirations of the existing patents range from 2019 to 2039 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of $0.1 million and 0.2 million were abandoned and were charged to research and development expenses in the statement of operations for the three months ended April 30, 2019 and 2018, respectively. Patent applications having a net book value of 0.4 million and $0.3 million were abandoned and were charged to research and development expenses in the statement of operations for the six months ended April 30, 2019 and 2018, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $0.1 million for each of the three months ended April 30, 2019 and 2018, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $0.2 million for each of the six months ended April 30, 2019 and 2018, respectively.

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-NEO, ADXS-HOT, ADXS-PSA and ADXS-HER2 and other products that are in development or out-licensed. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding our studies and developing our intellectual property, the Company would likely record an impairment to certain of these assets.

At April 30, 2019, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Year ended October 31,

2019 (Remaining)	$	193
2020		372
2021		352
2022		352
2023		352
Thereafter		3,330
Total	$	4,951

Accrued Expenses

6 Months Ended

Apr. 30, 2019

Payables and Accruals [Abstract]

Accrued Expenses

5. ACCRUED EXPENSES:

	April 30, 2019		October 31, 2018

Salaries and other compensation	$	1,388	$	2,035
Vendors		1,293		3,660
Professional fees		908		490
Total accrued expenses	$	3,589	$	6,185

Common Stock Purchase Warrants and Warrant Liability

6 Months Ended

Apr. 30, 2019

Common Stock Purchase Warrants And Warrant Liability

Common Stock Purchase Warrants and Warrant Liability

6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

As of April 30, 2019, there were outstanding warrants to purchase 72,304 shares of our common stock with exercise prices ranging from $3.72 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Amount		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	3.72		72,279	September 2024	Advaxis Public Offering
	Grand Total		72,304

As of October 31, 2018, there were outstanding warrants to purchase 944,635 shares of our common stock with exercise prices ranging from $22.50 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Amount		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	56.25		166	March 2019	Placement Agent- Advaxis Public Offering
$	22.50		944,444	September 2024	Advaxis Public Offering
	Grand Total		944,635

A summary of warrant activity was as follows (in thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2018		944,635		$	22.50		5.87	$	-
Exercised		(15,300	)		4.50
Exchanged		(856,865	)		22.50
Expired		(166	)		56.25
Outstanding and exercisable warrants at April 30, 2019		72,304		$	3.82		5.37	$	-

As of April 30, 2019, the Company had 25 of its total 72,304 outstanding warrants classified as equity (equity warrants). As of October 31, 2018, the Company had 191 of its total 944,635 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the relative fair value method, in the stockholders’ equity section of the balance sheet.

Shares Issued in Settlement of Warrants

On March 14, 2019, the Company entered into private exchange agreements with certain holders of warrants issued in connection with the Company’s September 2018 public offering of common stock and warrants. The warrants being exchanged provided for the purchase of up to an aggregate of 856,865 shares of the Company’s common stock at an exercise price of $22.50, with an expiration date of September 11, 2024. Pursuant to such exchange agreements, the Company issued 856,865 shares of common stock to the investors in exchange for such warrants on a 1:1 basis. The exchange of warrants for common stock caused the down round provision to be triggered and the exercise price of the warrants that were not exchanged were reduced from $22.50 to $4.50. The warrants were valued at approximately $3.9 million on the March 14, 2019 using the Monte Carlo Model. In determining the fair warrant of the warrants issued on March 14, 2019, the Company used the following inputs in its Monte Carlo Model: exercise price $22.50, stock price $6.45, expected term 5.50 years, volatility 96.37% and risk free interest rate 2.44%. In connection with the exchange of warrants for common stock, the Company recorded a loss of approximately $1.6 million as the fair value of the shares issued exceeded the fair value of warrants exchanged.

Warrant Liability

As of April 30, 2019, the Company had 72,279 of its total 72,304 outstanding warrants classified as liabilities (liability warrants). As of October 31, 2018, the Company had 944,444 of its total 944,635 outstanding warrants classified as liabilities (liability warrants). These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. In April 2019, the down round feature was triggered a second time due to sale of 2,500,000 common shares (see Note 11) and the exercise price of the warrants were reduced from $4.50 to $3.72. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which net cash settlement would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo Simulation Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

As of April 30, 2019 and October 31, 2018, the fair value of the warrant liability was approximately $0.2 million and $6.5 million, respectively. For the three and six months ended April 30, 2019, the Company reported an expense of approximately $14,000 and income of approximately $2.4 million, respectively. For each of the three and six months ended April 30, 2018, the Company reported income of approximately $0.

In measuring the warrant liability at April 30, 2019 and October 31, 2018, the Company used the following inputs in its Monte Carlo simulation model:

	April 30, 2019			October 31, 2018
Exercise Price	$	3.72		$	22.50
Stock Price	$	3.54		$	8.40
Expected Term		5.37 years			5.87 years
Volatility %		93.87	%		97.47	%
Risk Free Rate		2.28	%		3.03	%

Share Based Compensation

6 Months Ended

Apr. 30, 2019

Share-based Payment Arrangement [Abstract]

Share Based Compensation

7. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the Statement of Operations (in thousands):

	Three Months Ended April 30,				Six Months Ended April 30,
	2019		2018		2019		2018
Research and development	$	258	$	526	$	581	$	1,799
General and administrative		221		699		520		2,235
Total	$	479	$	1,225	$	1,101	$	4,034

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the six months ended April 30, 2019 is as follows:

	Number of RSUs			Weighted-Average Grant Date Fair Value

Balance at October 31, 2018		32,614		$	70.41
Vested		(10,541	)		70.49
Cancelled		(5,010	)		110.69
Balance at April 30, 2019		17,063		$	58.54

As of April 30, 2019, there was approximately $0.7 million of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.16 years.

As of April 30, 2019, the aggregate intrinsic value of non-vested RSU’s was approximately $60,000.

Employee Stock Awards

Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 692 shares and 17,107 shares (13,873 shares on a net basis after employee taxes) during the three months ended April 30, 2019 and 2018, respectively. Total stock compensation expense associated with employee awards for the three months ended April 30, 2019 and 2018 was approximately $0.2 million and $0.6 million, respectively

Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 10,539 shares and 30,252 shares (26,876 shares on a net basis after employee taxes) during the six months ended April 30, 2019 and 2018 respectively. Total stock compensation expense associated with employee awards for the six months ended April 30, 2019 and 2018 was approximately $0.5 million and $2.0 million, respectively.

Included in compensation expense for the three and six months ended April 30, 2018 is approximately $0.2 million recognized as a result of the modification of certain RSU’s associated with the resignation of the Company’s Chief Financial Officer in April 2018. Pursuant to the separation agreement, the vesting was accelerated on all the outstanding RSU’s.

Director Stock Awards

Common stock issued to Directors for compensation related to board and committee membership totaled 0 shares and 2,000 shares for three months ended April 30, 2019 and 2018, respectively. During the three months ended April 30, 2019 and 2018, total stock compensation expense associated with Director awards was approximately $0 and $6,000 respectively.

Common stock issued to Directors for compensation related to board and committee membership totaled 0 shares and 2,000 shares for the six months ended April 30, 2019 and 2018, respectively. During the six months ended April 30, 2019 and 2018, total stock compensation expense associated with Director awards was $0 and $0.1 million, respectively.

Included in compensation expense for the three and six months ended April 30, 2018 is approximately $10,000 recognized as a result of the modification of certain RSU’s associated with the end of service of a former Board member. The vesting was accelerated on all the outstanding RSU’s.

Stock Options

A summary of changes in the stock option plan for the six months ended April 30, 2019 is as follows:

	Number of Options			Weighted-Average Exercise Price
Outstanding at October 31, 2018:		330,071		$	122.79
Granted		86,882			6.50
Canceled or Expired		(16,693	)		20.20
Outstanding at April 30, 2019		400,260			101.82
Vested and Exercisable at April 30, 2019		235,097		$	160.03

Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three months ended April 30, 2019 and 2018 was approximately $0.3 million and $0.6 million, respectively. For the six months ended April 30, 2019 and 2018, compensation cost related to the Company’s outstanding stock options was approximately $0.6 million and $2.0 million, respectively. Included in compensation expense for the three and six months ended April 30, 2018 is approximately $0.1 million recognized as a result of the modification of certain option agreements associated with the end of service of two former Board members. For the modified options, the vesting was accelerated and the expiration dates were changed to the earlier of the original expiration date or March 21, 2023.

As of April 30, 2019, there was approximately $1.9 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.92 years.

As of April 30, 2019, the aggregate intrinsic value of vested and exercisable options was $0.

In determining the fair value of the stock options granted during the six months ended April 30, 2019 and 2018, the Company used the following inputs in its Black Scholes Merton model:

	Six Months Ended April 30,
	2019			2018

Expected Term		5.50 – 6.51 years			5.35 – 6.51 years
Expected Volatility		90.29 – 104.20	%		95.11 – 100.34	%
Expected Dividends		0	%		0	%
Risk Free Interest Rate		2.39 – 3.15	%		1.81 – 2.66	%

Employee Stock Purchase Plan

During the six months ended April 30, 2019, the Company issued 3,512 shares that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

During the six months ended April 30, 2018, the Company issued 712 shares that were purchased under the 2015 Employee Stock Purchase Plan (“ESPP”).

Net Income (Loss) Per Share

6 Months Ended

Apr. 30, 2019

Earnings Per Share [Abstract]

Net Income (Loss) Per Share

8. NET INCOME (LOSS) PER SHARE

Basic and diluted earnings per share is calculated as follows (in thousands, except share and per share data):

	Three Months Ended April 30,
	2019			2018
Numerator:
Net loss	$	(9,383	)	$	(13,408	)
Loss attributable to common stockholders – basic and diluted		(9,383	)		(13,408	)

Denominator:
Weighted-average number of common shares used in earnings per share – basic and diluted		5,900,449			3,324,320

Loss per share – basic and diluted	$	(1.59	)	$	(4.03	)

	Six Months Ended April 30,
	2019			2018
Numerator:
Net income (loss)	$	3,434		$	(33,900	)
Income (loss) attributable to common stockholders – basic		3,434			(33,900	)
Effect of liability classified warrants		(2,395	)		-
Income (loss) attributable to common stockholders – diluted		1,039			(33,900	)

Denominator:
Weighted-average number of common shares used in earnings per share - basic		5,259,677			3,038,439
Effect of dilutive stock options		61			-
Effect of dilutive warrants		23,034			-
Weighted-average number of common shares used in earnings per share - diluted		5,282,772			3,038,439

Income (loss) per share – basic	$	0.65		$	(11.16	)
Income (loss) per share – diluted	$	0.20		$	(11.16	)

The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive:

	As of April 30,
	2019		2018
Warrants		72,304		206,160
Stock options		235,097		309,534
Restricted stock units		17,063		72,632
Total		324,464		588,326

Collaboration and Licensing Agreements

6 Months Ended

Apr. 30, 2019

Business Combinations [Abstract]

Collaboration and Licensing Agreements

9. COLLABORATION AND LICENSING AGREEMENTS

Amgen

On August 1, 2016, the Company entered into a global agreement (the “Amgen Agreement”) with Amgen for the development and commercialization of the Company’s ADXS-NEO, a novel, preclinical investigational immunotherapy, using the Company’s proprietary Listeria monocytogenes attenuated bacterial vector which activates a patient’s immune system to respond against unique mutations, or neoepitopes, contained in and identified from an individual patient’s tumor. Under the terms of the Amgen Agreement, Amgen received an exclusive worldwide license to develop and commercialize ADXS-NEO. Amgen made an upfront payment to Advaxis of $40 million and purchased directly from Advaxis 203,163 shares of the Company’s common stock, at approximately $123.00 per share (representing a purchase at market using a 20 day VWAP methodology) for a total of $25 million. Amgen assisted in funding the clinical development and commercialization of ADXS-NEO and Advaxis retained manufacturing responsibilities. Advaxis and Amgen collaborated through a joint steering committee for the development and commercialization of ADXS-NEO. Advaxis received reimbursements for research and development costs and Advaxis was eligible to receive future contingent payments based on development, regulatory and sales milestone payments of up to $475 million and high single digit to double digit royalty payments based on worldwide sales by Amgen.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Amgen, is a customer. The Company identified the following material promises under the arrangement: (1) licenses, (2) research and development activities, (3) clinical supplies, (4) regulatory responsibilities and (5) participation on a Joint Steering Committee (JSC). The Company determined that the licenses and research and development activities were not distinct from another, as the licenses had limited value without the performance of the research and development activities. Participation on the JSC to oversee the research and development activities was determined to be quantitatively and qualitatively immaterial and therefore was excluded from performance obligations. The clinical supply and regulatory responsibilities did not represent separate performance obligations based on their dependence on the research and development efforts. Based on this assessment, the Company identified one performance obligation at the outset of the Amgen Agreement, which consists of: (1) licenses, (2) research and development activities, (3) clinical supplies and (4) regulatory responsibilities.

Under the Amgen Agreement, in order to evaluate the appropriate transaction price, the Company determined that the upfront amount of $40 million constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which is allocated to the single performance obligation. The Company concluded that a time-based method was most appropriate to measuring progress toward completion given that the research and development services are satisfied reasonably evenly over the agreement and the Company has a stand-ready obligation to perform over such time. Accordingly, progress toward completion and related revenue recognition is measured using the input method of time elapsed relative to the estimated timeline for Advaxis to submit the Phase 2 package to Amgen, or perform the contractual research and development services, which was the predominant promise in the Company’s combined performance obligation to Amgen.

The reimbursement for the research and development costs was variable consideration that was included in the transaction price at the outset, subject to the constraint. The Company estimated the consideration from the reimbursement of the research and development costs using the most-likely amount. When the research and development costs are no longer constrained, they are added to the transaction price for the single, combined performance obligation and recognized over the same recognition period as the rest of the performance obligation’s allocated revenue. The potential milestone and sales-based royalty payments that the Company was eligible to receive were excluded from the transaction price, as all milestone and sales royalty amounts were fully constrained based on the probability of achievement. The Company reevaluated the transaction price at the end of each reporting period and as uncertain events were resolved or other changes in circumstances occurred, and, as necessary, adjusted its estimate of the transaction price.

On December 10, 2018, the Company received a written notice of termination from Amgen with respect to the Amgen Agreement. The termination became effective as of February 8, 2019. The Company is currently enrolling patients in its ADXS-NEO program and evaluating its options for partnering the program. Pursuant to the terms of the Amgen Agreement, upon Amgen’s termination, the license to Amgen terminated and the Company regained worldwide rights for the development and commercialization of its ADXS-NEO program.

The remaining deferred revenue of approximately $18.2 million on December 10, 2018 related to the $40 million non-refundable, up-front payment received from Amgen was accounted for as of the modification date. As of that notification date, the Company adjusted revenue on a cumulative catch-up basis considering the revised measure of progress for the combined performance obligation based on the modified service period up to and through the contract termination date of February 8, 2019. The Company recognized cumulative catch-up revenue of approximately $15.6 million on December 10, 2018. The remaining $2.6 million was recognized over the subsequent 60 days until the performance obligation was satisfied on February 8, 2019.

During the three months ended April 30, 2019 and 2018, the Company recognized revenue from the Amgen Agreement of approximately $1.2 million and $1.7 million, respectively. During the six months ended April 30, 2019 and 2018, the Company recognized revenue from the Amgen Agreement of approximately $20.6 million and $3.6 million, respectively. During the three and six months ended April 30, 2018, Company recorded reductions in research and development expenses of approximately $1.6 million and $3.1 million, respectively, pertaining to the reimbursement of research and development costs. During the three and six months ended January 31, 2019, the reimbursement of research and development costs of approximately $0.8 million and $2.0 million, respectively, was included in revenue.

Aratana Therapeutics

On March 19, 2014, the Company and Aratana entered into a definitive Exclusive License Agreement (the “Aratana Agreement”). Pursuant to the Agreement, Advaxis granted Aratana an exclusive, worldwide, royalty-bearing, license, with the right to sublicense, certain Advaxis proprietary technology that enables Aratana to develop and commercialize animal health products that will be targeted for treatment of osteosarcoma and other cancer indications in animals. Under the terms of the Aratana Agreement, Aratana paid an upfront payment to the Company, of $1 million. As this license has stand-alone value to Aratana (who has the ability to sublicense) and was delivered to Aratana, upon execution of the Aratana Agreement, the Company recorded the $1 million payment as licensing revenue during the year ended October 31, 2014. Aratana will also pay the Company up to an additional $36.5 million based on the achievement of certain milestones with respect to the advancement of products pursuant to the terms of the Aratana Agreement. In addition, Aratana may pay the Company an additional $15 million in cumulative sales milestones pursuant to the terms of the Aratana Agreement.

Advaxis (i) issued and sold 20,408 shares of Advaxis’ common stock to Aratana at a price of $73.50 per share, which was equal to the closing price of the common stock on the NASDAQ Capital Market on March 19, 2014, and (ii) issued a ten-year warrant to Aratana giving Aratana the right to purchase up to 10,204 additional shares of Advaxis’ common stock at an exercise price of $73.50 per share. In connection with the sale of the common stock and warrants, Advaxis received aggregate net proceeds of $1.5 million. Aratana exercised all of its 10,204 warrants. As a result, no warrants remain outstanding under this agreement.

During the year ended October 31, 2018, the USDA’s Center for Veterinary Biologics granted Aratana conditional approval for its canine osteosarcoma vaccine using Advaxis’ technology. During the three months ended April 30, 2019 and 2018, Advaxis recognized royalty revenue totaling approximately $0 and $3,000, respectively, from Aratana’s sales of the canine osteosarcoma vaccine. During the six months ended April 30, 2019 and 2018, Advaxis recognized royalty revenue totaling approximately $2,000 and $3,000, respectively, from Aratana’s sales of the canine osteosarcoma vaccine.

Global BioPharma Inc.

On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC).

GBP is planning to conduct a randomized Phase 2, open-label, controlled trial in HPV-associated NSCLC in patients following first-line induction chemotherapy. GBP has obtained Taiwanese regulatory approval for this trial and plans to initiate this trial in 2019. This trial will be fully funded exclusively by GBP and GBP will be responsible for all clinical development and commercialization costs in the GBP territory and GBP is committed to establishing manufacturing capabilities for its own. Under the terms of the agreement, the Company will exclusively license the rights of axalimogene filolisbac to GBP for the Asia, Africa, and former USSR territory, exclusive of India and certain other countries, for all HPV-associated indications. Advaxis will retain exclusive rights to axalimogene filolisbac for the rest of the world.

During each of the six months ended April 30, 2019 and 2018, the Company recorded $0.25 million in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews. In addition, GBP has paid $2.25 million to the contract research organization that manages the Company’s AIM2CERV clinical trial.

Commitments and Contingencies

6 Months Ended

Apr. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

Stendhal

On September 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013) relating to the Co-development and Commercialization Agreement with Especificos Stendhal SA de CV (the “Stendhal Agreement”). In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regarding its AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at the time and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking to recover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3 million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answered Stendhal’s Demand for Arbitration and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhal breached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and that Stendhal therefore owes the Company $3 million.

On April 2, 2019, the Arbitrator denied the Company’s early application for summary disposition of Stendhal’s claims. As a result, the arbitration will proceed to a hearing, scheduled to begin on October 21, 2019. On April 26, 2019, Stendhal served its Statement of Claim, and on May 23, 2019, the Company served its Statement of Defense and Counterclaim. At this time, the Company is unable to predict the likelihood of an unfavorable outcome.

Stockholders' Equity

6 Months Ended

Apr. 30, 2019

Equity [Abstract]

Stockholders' Equity

11. STOCKHOLDERS’ EQUITY

A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2019 and 2018 is presented below (in thousands, except share data):

	Preferred Stock				Common Stock				Additional Paid-In			Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance at November 1, 2017		-	$	-		2,744,196	$	3	$	355,400		$	(301,142	)	$	54,261
Stock based compensation						13,003		-		2,854			-			2,854
Tax withholdings paid related to net share settlement of equity awards						-		-		(7	)		-			(7	)
Tax withholdings paid on equity awards						-		-		(209	)		-			(209	)
Tax shares sold to pay for tax withholdings on equity awards						-		-		197			-			197
Issuance of shares to employees under ESPP Plan						-		-		-			-			-
Advaxis at-the-market sales						58,776		-		2,659			-			2,659
Net Loss						-		-		-			(20,492	)		(20,492	)
Balance at January 31, 2018		-	$	-		2,815,975	$	3	$	360,894		$	(321,634	)	$	39,263
Stock based compensation						17,873		-		1,225			-			1,225
Tax withholdings paid related to net share settlement of equity awards						-		-		(33	)		-			(33	)
Tax withholdings paid on equity awards						-		-		(61	)		-			(61	)
Tax shares sold to pay for tax withholdings on equity awards						-		-		78			-			78
Issuance of shares to employees under ESPP Plan						712		-		9			-			9
Advaxis public offerings						666,667		1		18,382			-			18,383
Net Loss						-		-		-			(13,407	)		(13,407	)
Balance at April 30, 2018		-	$	-		3,501,227	$	4	$	380,494		$	(335,041	)	$	45,457

	Preferred Stock				Common Stock				Additional Paid-In			Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance at November 1, 2018		-	$	-		4,634,189	$	5	$	391,703		$	(367,657	)	$	24,051
Stock based compensation						9,811		-		622			-			622
Tax withholdings paid on equity awards						-		-		(11	)		-			(11	)
Tax shares sold to pay for tax withholdings on equity awards						-		-		11			-			11
Issuance of shares to employees under ESPP Plan						2,007		-		9			-			9
ESPP Expense						-		-		1						1
Net Income						-				-			12,817			12,817
Balance at January 31, 2019		-	$	-		4,646,007	$	5	$	392,335		$	(354,840	)	$	37,500
Stock based compensation						693		-		479			-			479
Tax withholdings paid on equity awards						-		-		(3	)		-			(3	)
Tax shares sold to pay for tax withholdings on equity awards						-		-		3			-			3
Issuance of shares to employees under ESPP Plan						1,505		-		7			-			7
Warrant exercises						15,300		-		68			-			68
Warrant liability reclassified into equity						-		-		53			-			53
ESPP Expense						-		-		1						1
Shares issued in settlement of warrants						856,865		1		5,462			-			5,463
Advaxis public offerings						2,500,000		2		8,980			-			8,982
Net Loss						-		-		-			(9,383	)		(9,383	)
Balance at April 30, 2019		-	$	-		8,020,370	$	8	$	407,385		$	(364,223	)	$	43,170

During the six months ended April 30, 2018, the Company sold 58,775 shares of its Common Stock at-the-market transactions resulting in net proceeds of approximately $2.7 million.

During February 2018, the Company issued 666,667 shares of the Company’s common stock in a public offering at $30.00 per share, less underwriting discounts and commissions. The net proceeds to the Company from the transaction was approximately $18.4 million.

During April 2019, the Company issued 2,500,000 shares of the Company’s common stock in a public offering at $4.00 per share, less underwriting discounts and commissions. The net proceeds to the Company from the transaction was approximately $9 million.

On February 21, 2019, the Company’s stockholders voted to approve an amendment to increase the number of authorized shares of common stock from 95,000,000 to 170,000,000 and also voted to approve an amendment to allow the Company to execute a reverse stock split of common stock at the discretion of the Board of Directors. The amendment to increase the number of authorized shares of common stock became effective upon filing of the amendment with the Secretary of State of the State of Delaware on February 28, 2019. Additionally, on March 29, 2019, the Company executed a 1 for 15 reverse stock split.

Income Taxes

6 Months Ended

Apr. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

12. INCOME TAXES

The Company did not record any income tax expense associated with its net income for the six months ended April 30, 2019, as the Company expects to incur a net loss for the 2019 fiscal year.

Fair Value

6 Months Ended

Apr. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value

13. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2019 and October 31, 2018 (in thousands):

April 30, 2019		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $3.72 through September 2024			-				-			$	213			$	213

October 31, 2018		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $22.50 through September 2024			-				-			$	6,517			$	6,517

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities:

	April 30, 2019
Beginning balance	$	6,517
Shares issued in settlement of warrants		(3,856	)
Warrant exercises		(53	)
Change in fair value		2,395
Ending Balance	$	213

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies and Basis of Presentation (Policies)

6 Months Ended

Apr. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation/Estimates

Basis of Presentation/Estimates

Reclassification

Reclassification

Concentration of Credit Risk

Concentration of Credit Risk

Restricted Cash and Letters of Credit

Restricted Cash and Letters of Credit

Revenue Recognition

Revenue Recognition

Collaborative Arrangements

Collaborative Arrangements

Recent Accounting Standards

Recent Accounting Standards

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

	Impact of ASC 606 Adoption on Condensed Balance Sheet as of November 1, 2018
(in thousands)	As reported under ASC 606		Adjustments			Balances without adoption of ASC 606
Accounts receivable	$	1,664	$	1,664		$	-
Prepaid expenses and other current assets	$	1,611	$	(1,664	)	$	3,275

	Impact of ASC 606 Adoption on Condensed Balance Sheet as of April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,587	$	-	$	1,587

	Impact of ASC 606 Adoption on Condensed Statement of Operations for the Three Months Ended April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Revenue	$	1,188	$	73	$	1,115
Research and Development Expenses	$	6,327	$	73	$	6,254

	Impact of ASC 606 Adoption on Condensed Statement of Operations for the Six Months Ended April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Revenue	$	20,877	$	1,960	$	18,917
Research and Development Expenses	$	13,032	$	1,960	$	11,072

	Impact of ASC 606 Adoption on Condensed Statement of Cash Flows for the Six Months Ended April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,587	$	-	$	1,587

Summary of Significant Accounting Policies and Basis of Presentation (Tables)

6 Months Ended

Apr. 30, 2019

Accounting Policies [Abstract]

Schedule of Reclassifications to Balance Sheet and Income Statement

A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below (in thousands):

	Impact of ASC 606 Adoption on Condensed Balance Sheet as of November 1, 2018
(in thousands)	As reported under ASC 606		Adjustments			Balances without adoption of ASC 606
Accounts receivable	$	1,664	$	1,664		$	-
Prepaid expenses and other current assets	$	1,611	$	(1,664	)	$	3,275

	Impact of ASC 606 Adoption on Condensed Balance Sheet as of April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,587	$	-	$	1,587

	Impact of ASC 606 Adoption on Condensed Statement of Operations for the Three Months Ended April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Revenue	$	1,188	$	73	$	1,115
Research and Development Expenses	$	6,327	$	73	$	6,254

	Impact of ASC 606 Adoption on Condensed Statement of Operations for the Six Months Ended April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Revenue	$	20,877	$	1,960	$	18,917
Research and Development Expenses	$	13,032	$	1,960	$	11,072

	Impact of ASC 606 Adoption on Condensed Statement of Cash Flows for the Six Months Ended April 30, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,587	$	-	$	1,587

Property and Equipment (Tables)

6 Months Ended

Apr. 30, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment, net consists of the following (in thousands):

	April 30, 2019			October 31, 2018

Leasehold improvements	$	2,335		$	2,321
Laboratory equipment		5,530			5,510
Furniture and fixtures		746			746
Computer equipment		409			409
Construction in progress		17			17
Total property and equipment		9,037			9,003
Accumulated depreciation and amortization		(2,880	)		(2,319	)
Net property and equipment	$	6,157		$	6,684

Intangible Assets (Tables)

6 Months Ended

Apr. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

Intangible assets, net consist of the following (in thousands):

	April 30, 2019			October 31, 2018

Patents	$	6,240		$	5,970
Licenses		777			777
Software		117			117
Total intangibles		7,134			6,864
Accumulated amortization		(2,183	)		(2,026	)
Intangible assets	$	4,951		$	4,838

Schedule of Carrying Value of Intangible Assets

At April 30, 2019, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Year ended October 31,

2019 (Remaining)	$	193
2020		372
2021		352
2022		352
2023		352
Thereafter		3,330
Total	$	4,951

Accrued Expenses (Tables)

6 Months Ended

Apr. 30, 2019

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

	April 30, 2019		October 31, 2018

Salaries and other compensation	$	1,388	$	2,035
Vendors		1,293		3,660
Professional fees		908		490
Total accrued expenses	$	3,589	$	6,185

Common Stock Purchase Warrants and Warrant Liability (Tables)

6 Months Ended

Apr. 30, 2019

Common Stock Purchase Warrants And Warrant Liability

Schedule of Outstanding Warrants

Exercise Price		Amount		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	3.72		72,279	September 2024	Advaxis Public Offering
	Grand Total		72,304

Exercise Price		Amount		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	56.25		166	March 2019	Placement Agent- Advaxis Public Offering
$	22.50		944,444	September 2024	Advaxis Public Offering
	Grand Total		944,635

Schedule of Warrants Activity

A summary of warrant activity was as follows (in thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2018		944,635		$	22.50		5.87	$	-
Exercised		(15,300	)		4.50
Exchanged		(856,865	)		22.50
Expired		(166	)		56.25
Outstanding and exercisable warrants at April 30, 2019		72,304		$	3.82		5.37	$	-

Schedule of Assumptions Used in Warrant Liability

In measuring the warrant liability at April 30, 2019 and October 31, 2018, the Company used the following inputs in its Monte Carlo simulation model:

	April 30, 2019			October 31, 2018
Exercise Price	$	3.72		$	22.50
Stock Price	$	3.54		$	8.40
Expected Term		5.37 years			5.87 years
Volatility %		93.87	%		97.47	%
Risk Free Rate		2.28	%		3.03	%

Share Based Compensation (Tables)

6 Months Ended

Apr. 30, 2019

Share-based Payment Arrangement [Abstract]

Summary of Share Based Compensation Expense

The following table summarizes share-based compensation expense included in the Statement of Operations (in thousands):

	Three Months Ended April 30,				Six Months Ended April 30,
	2019		2018		2019		2018
Research and development	$	258	$	526	$	581	$	1,799
General and administrative		221		699		520		2,235
Total	$	479	$	1,225	$	1,101	$	4,034

Summary of RSU Activity and Related Information

A summary of the Company’s RSU activity and related information for the six months ended April 30, 2019 is as follows:

	Number of RSUs			Weighted-Average Grant Date Fair Value

Balance at October 31, 2018		32,614		$	70.41
Vested		(10,541	)		70.49
Cancelled		(5,010	)		110.69
Balance at April 30, 2019		17,063		$	58.54

Summary of Changes in Stock Option Plan

A summary of changes in the stock option plan for the six months ended April 30, 2019 is as follows:

	Number of Options			Weighted-Average Exercise Price
Outstanding at October 31, 2018:		330,071		$	122.79
Granted		86,882			6.50
Canceled or Expired		(16,693	)		20.20
Outstanding at April 30, 2019		400,260			101.82
Vested and Exercisable at April 30, 2019		235,097		$	160.03

Summary of Fair Value of Stock Options Granted of BSM

In determining the fair value of the stock options granted during the six months ended April 30, 2019 and 2018, the Company used the following inputs in its Black Scholes Merton model:

	Six Months Ended April 30,
	2019			2018

Expected Term		5.50 – 6.51 years			5.35 – 6.51 years
Expected Volatility		90.29 – 104.20	%		95.11 – 100.34	%
Expected Dividends		0	%		0	%
Risk Free Interest Rate		2.39 – 3.15	%		1.81 – 2.66	%

Net Income (Loss) Per Share (Tables)

6 Months Ended

Apr. 30, 2019

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Earnings Per Share

Basic and diluted earnings per share is calculated as follows (in thousands, except share and per share data):

	Three Months Ended April 30,
	2019			2018
Numerator:
Net loss	$	(9,383	)	$	(13,408	)
Loss attributable to common stockholders – basic and diluted		(9,383	)		(13,408	)

Denominator:
Weighted-average number of common shares used in earnings per share – basic and diluted		5,900,449			3,324,320

Loss per share – basic and diluted	$	(1.59	)	$	(4.03	)

	Six Months Ended April 30,
	2019			2018
Numerator:
Net income (loss)	$	3,434		$	(33,900	)
Income (loss) attributable to common stockholders – basic		3,434			(33,900	)
Effect of liability classified warrants		(2,395	)		-
Income (loss) attributable to common stockholders – diluted		1,039			(33,900	)

Denominator:
Weighted-average number of common shares used in earnings per share - basic		5,259,677			3,038,439
Effect of dilutive stock options		61			-
Effect of dilutive warrants		23,034			-
Weighted-average number of common shares used in earnings per share - diluted		5,282,772			3,038,439

Income (loss) per share – basic	$	0.65		$	(11.16	)
Income (loss) per share – diluted	$	0.20		$	(11.16	)

Schedule of Diluted Weighted-Average Shares Outstanding

	As of April 30,
	2019		2018
Warrants		72,304		206,160
Stock options		235,097		309,534
Restricted stock units		17,063		72,632
Total		324,464		588,326

Stockholders' Equity (Tables)

6 Months Ended

Apr. 30, 2019

Equity [Abstract]

Summary of Changes in Stockholders' Equity

A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2019 and 2018 is presented below (in thousands, except share data):

	Preferred Stock				Common Stock				Additional Paid-In			Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance at November 1, 2017		-	$	-		2,744,196	$	3	$	355,400		$	(301,142	)	$	54,261
Stock based compensation						13,003		-		2,854			-			2,854
Tax withholdings paid related to net share settlement of equity awards						-		-		(7	)		-			(7	)
Tax withholdings paid on equity awards						-		-		(209	)		-			(209	)
Tax shares sold to pay for tax withholdings on equity awards						-		-		197			-			197
Issuance of shares to employees under ESPP Plan						-		-		-			-			-
Advaxis at-the-market sales						58,776		-		2,659			-			2,659
Net Loss						-		-		-			(20,492	)		(20,492	)
Balance at January 31, 2018		-	$	-		2,815,975	$	3	$	360,894		$	(321,634	)	$	39,263
Stock based compensation						17,873		-		1,225			-			1,225
Tax withholdings paid related to net share settlement of equity awards						-		-		(33	)		-			(33	)
Tax withholdings paid on equity awards						-		-		(61	)		-			(61	)
Tax shares sold to pay for tax withholdings on equity awards						-		-		78			-			78
Issuance of shares to employees under ESPP Plan						712		-		9			-			9
Advaxis public offerings						666,667		1		18,382			-			18,383
Net Loss						-		-		-			(13,407	)		(13,407	)
Balance at April 30, 2018		-	$	-		3,501,227	$	4	$	380,494		$	(335,041	)	$	45,457

	Preferred Stock				Common Stock				Additional Paid-In			Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance at November 1, 2018		-	$	-		4,634,189	$	5	$	391,703		$	(367,657	)	$	24,051
Stock based compensation						9,811		-		622			-			622
Tax withholdings paid on equity awards						-		-		(11	)		-			(11	)
Tax shares sold to pay for tax withholdings on equity awards						-		-		11			-			11
Issuance of shares to employees under ESPP Plan						2,007		-		9			-			9
ESPP Expense						-		-		1						1
Net Income						-				-			12,817			12,817
Balance at January 31, 2019		-	$	-		4,646,007	$	5	$	392,335		$	(354,840	)	$	37,500
Stock based compensation						693		-		479			-			479
Tax withholdings paid on equity awards						-		-		(3	)		-			(3	)
Tax shares sold to pay for tax withholdings on equity awards						-		-		3			-			3
Issuance of shares to employees under ESPP Plan						1,505		-		7			-			7
Warrant exercises						15,300		-		68			-			68
Warrant liability reclassified into equity						-		-		53			-			53
ESPP Expense						-		-		1						1
Shares issued in settlement of warrants						856,865		1		5,462			-			5,463
Advaxis public offerings						2,500,000		2		8,980			-			8,982
Net Loss						-		-		-			(9,383	)		(9,383	)
Balance at April 30, 2019		-	$	-		8,020,370	$	8	$	407,385		$	(364,223	)	$	43,170

Fair Value (Tables)

6 Months Ended

Apr. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2019 and October 31, 2018 (in thousands):

April 30, 2019		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $3.72 through September 2024			-				-			$	213			$	213

October 31, 2018		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $22.50 through September 2024			-				-			$	6,517			$	6,517

Schedule of Changes in the Fair Value of Warrant Liabilities

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities:

	April 30, 2019
Beginning balance	$	6,517
Shares issued in settlement of warrants		(3,856	)
Warrant exercises		(53	)
Change in fair value		2,395
Ending Balance	$	213

Nature of Operations (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Apr. 30, 2019	Oct. 31, 2018	Apr. 30, 2018
Cash and cash equivalents	$ 33,706	$ 44,141	$ 48,877
October 2013 Through April 2019 [Member]
Proceeds from public offering	$ 275,000

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Reclassifications to Balance Sheet and Income Statement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Nov. 02, 2018	Oct. 31, 2018
Accounts receivable					$ 1,664	$ 1,664
Prepaid expenses and other current assets	1,587		1,587		1,611	$ 1,611
Revenue	1,188	$ 1,747	20,877	$ 3,803
Research and Development Expenses	5,969	$ 10,368	12,675	27,119
Accounts receivable			1,664	1,161
Prepaid expenses and other current assets			(994)	$ (1,765)
Adjustments [Member]
Accounts receivable					1,664
Prepaid expenses and other current assets					(1,664)
Revenue	73		1,960
Research and Development Expenses	73		1,960
Accounts receivable
Prepaid expenses and other current assets
Balances Without Adoption of ASC 606 [Member]
Accounts receivable
Prepaid expenses and other current assets	1,587		1,587		$ 3,275
Revenue	1,115		18,917
Research and Development Expenses	$ 6,254		11,072
Accounts receivable
Prepaid expenses and other current assets			$ 1,587

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 300	$ 300	$ 571	$ 544

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Apr. 30, 2019	Oct. 31, 2018
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,335	$ 2,321
Laboratory equipment	5,530	5,510
Furniture and fixtures	746	746
Computer equipment	409	409
Construction in progress	17	17
Total property and equipment	9,037	9,003
Accumulated depreciation and amortization	(2,880)	(2,319)
Net property and equipment	$ 6,157	$ 6,684

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived patents expirations year			The expirations of the existing patents range from 2019 to 2039
Book value patent applications, net	$ 100	$ 200	$ 357	$ 305
Intangible asset amortization expense	$ 100	$ 100	$ 193	$ 189

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Apr. 30, 2019	Oct. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 6,240	$ 5,970
Licenses	777	777
Software	117	117
Total intangibles	7,134	6,864
Accumulated amortization	(2,183)	(2,026)
Intangible assets	$ 4,951	$ 4,838

Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) $ in Thousands	Oct. 31, 2018 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2019 (Remaining)	$ 193
2020	372
2021	352
2022	352
2023	352
Thereafter	3,330
Total	$ 4,951

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Apr. 30, 2019	Oct. 31, 2018
Payables and Accruals [Abstract]
Salaries and other compensation	$ 1,388	$ 2,035
Vendors	1,293	3,660
Professional fees	908	490
Total accrued expenses	$ 3,589	$ 6,185

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 14, 2019	Apr. 30, 2019	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Oct. 31, 2018
Number of warrants to purchase common stock		72,304	72,304		72,304		944,635
Exercise price		$ 3.72	$ 3.72		$ 3.72		$ 22.50
Warrants outstanding		72,304	72,304		72,304		944,635
Warrants issued		25	25		25		191
Fair value of warrant liability					$ 200		$ 6,500
Loss on shares issued in settlement of warrants			$ 1,607		1,607
Number of common stock shares sold						58,775
Change in fair value of warrant liability			$ 14,000	$ 0	$ 2,400	$ 0
Warrant Liability [Member]
Warrants outstanding		72,304	72,304		72,304		944,635
Warrants issued		72,279	72,279		72,279		944,444
Fair value of warrant liability					$ 2,395
Exercise Price		$ 3.72	$ 3.72		$ 3.72		$ 22.50
Stock Price		$ 3.54	3.54		$ 3.54		$ 8.40
Expected Term					5 years 4 months 13 days		5 years 10 months 14 days
Volatility					93.87%		97.47%
Risk Free Rate					2.28%		3.03%
Number of common stock shares sold		2,500,000
Monte Carlo Model [Member]
Exercise Price	$ 22.50
Stock Price	$ 6.45
Expected Term	5 years 6 months
Volatility	96.37%
Risk Free Rate	2.44%
Private Exchange Agreement [Member]
Number of warrants to purchase common stock	856,865
Exercise price	$ 22.50
Warrant expiration	Sep. 11, 2024
Private Exchange Agreement [Member] \| Investor [Member]
Number of common stock shares issued	856,865
Fair value of warrant liability	$ 3,900
Minimum [Member]
Exercise price		$ 3.72	3.72		$ 3.72		$ 22.50
Expected Term					5 years 6 months	5 years 4 months 6 days
Minimum [Member] \| Warrant Liability [Member]
Exercise price		3.72	3.72		$ 3.72
Minimum [Member] \| Private Exchange Agreement [Member]
Exercise price	$ 4.50
Maximum [Member]
Exercise price		281.25	281.25		$ 281.25		$ 281.25
Expected Term					6 years 6 months 3 days	6 years 6 months 3 days
Maximum [Member] \| Warrant Liability [Member]
Exercise price		$ 4.50	$ 4.50		$ 4.50
Maximum [Member] \| Private Exchange Agreement [Member]
Exercise price	$ 22.50

Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Apr. 30, 2019	Oct. 31, 2018
Exercise Price	$ 3.72	$ 22.50
Amount	72,304	944,635
Exercise Price Range One [Member]
Exercise Price	$ 281.25	$ 281.25
Amount	25	25
Type of Financing	Other warrants	Other warrants
Exercise Price Range Two [Member]
Exercise Price	$ 3.72	$ 56.25
Amount	72,279	166
Expiration Date	Sep. 30, 2024	Sep. 30, 2024
Type of Financing	Advaxis Public Offering	Advaxis Public Offering
Exercise Price Range Three [Member]
Exercise Price		$ 22.50
Amount		944,444
Expiration Date		Mar. 30, 2019
Type of Financing		Placement Agent- Advaxis Public Offering

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details)	6 Months Ended
	Apr. 30, 2019 USD ($) $ / shares shares
Common Stock Purchase Warrants And Warrant Liability
Number of Warrants, Outstanding, Beginning balance \| shares	944,635
Number of Warrants, Exercised \| shares	(15,300)
Number of Warrants, Exchanged \| shares	(856,865)
Number of Warrants, Expired \| shares	(166)
Number of Warrants, Outstanding, Ending balance \| shares	72,304
Weighted-Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 22.50
Weighted-Average Exercise Price, Exercised \| $ / shares	4.50
Weighted-Average Exercise Price, Exchanged \| $ / shares	22.50
Weighted-Average Exercise Price, Expired \| $ / shares	56.25
Weighted-Average Exercise Price, Outstanding, Ending \| $ / shares	$ 3.82
Weighted Average Remaining Contractual Life In Years, Beginning	5 years 10 months 14 days
Weighted Average Remaining Contractual Life In Years, Ending	5 years 4 months 13 days
Aggregate Intrinsic Value, Beginning \| $
Aggregate Intrinsic Value, Ending \| $

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) - Warrant Liability [Member] - $ / shares	6 Months Ended	12 Months Ended
	Apr. 30, 2019	Oct. 31, 2018
Exercise Price	$ 3.72	$ 22.50
Stock Price	$ 3.54	$ 8.40
Expected Term	5 years 4 months 13 days	5 years 10 months 14 days
Volatility %	93.87%	97.47%
Risk Free Rate	2.28%	3.03%

Share Based Compensation (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Unrecognized compensation cost related to non-vested stock option awards	$ 1,900		$ 1,900
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			1 year 11 months 1 day
Options outstanding, intrinsic value	0		$ 0
Stock compensation expense	479	$ 1,225	1,101	$ 4,034
Compensation cost related to outstanding stock options	300	600	$ 600	$ 200
Share-based compensation options expiration date			Mar. 21, 2023
2018 Employee Stock Purchase Plan [Member]
Number of shares issued under employee stock purchase plan'			3,512
2015 Employee Stock Purchase Plan [Member]
Number of shares issued under employee stock purchase plan'				712
Two Former Board Members [Member]
Stock compensation expense	100		$ 100
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards	700		$ 700
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			1 year 1 month 27 days
Options outstanding, intrinsic value	$ 60		$ 60
Stock compensation expense		10		$ 10
Restricted Stock Units (RSUs) [Member] \| Chief Financial Officer [Member]
Stock compensation expense		$ 200		$ 200
Employee Stock Awards [Member]
Share-based compensation, common stock, shares	692	17,107	10,539	30,252
Share-based compensation, shares on net basis after employee payroll taxes	13,873	13,873	26,876	26,876
Stock compensation expense	$ 200	$ 600	$ 500	$ 2,000
Director Stock Awards [Member]
Stock compensation expense	$ 0	$ 6	$ 0	$ 100
Issuance of common stock issued for share based compensation	0	2,000	0	2,000

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Share-based compensation expense	$ 479	$ 1,225	$ 1,101	$ 4,034
Research and Development [Member]
Share-based compensation expense	258	526	581	1,799
General and Administrative [Member]
Share-based compensation expense	$ 221	$ 699	$ 520	$ 2,235

Share Based Compensation - Summary of RSU Activity and Related Information (Details)	6 Months Ended
	Apr. 30, 2019 $ / shares shares
Number of RSUs Cancelled	(16,693)
Restricted Stock Units (RSUs) [Member]
Number of RSUs, Beginning Balance	32,614
Number of RSUs Vested	(10,541)
Number of RSUs Cancelled	(5,010)
Number of RSUs, Ending Balance	17,063
Weighted-Average Grant Date Fair Value, Outstanding, Beginning \| $ / shares	$ 70.41
Weighted-Average Grant Date Fair Value, Vested \| $ / shares	70.49
Weighted-Average Grant Date Fair Value, Cancelled \| $ / shares	110.69
Weighted-Average Grant Date Fair Value, Outstanding, Ending \| $ / shares	$ 58.54

Share Based Compensation - Summary of Changes in Stock Option Plan (Details)	6 Months Ended
	Apr. 30, 2019 $ / shares shares
Share-based Payment Arrangement [Abstract]
Number of Options, Beginning Balance \| shares	330,071
Number of Options, Granted \| shares	86,882
Number of Options, Canceled or Expired \| shares	(16,693)
Number of Options, Ending Balance \| shares	400,260
Number of Options, Vested and Exercisable \| shares	235,097
Weighted-Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 122.79
Weighted-Average Exercise Price, Granted \| $ / shares	6.50
Weighted-Average Exercise Price, Canceled or Expired \| $ / shares	20.20
Weighted-Average Exercise Price, Outstanding, Ending \| $ / shares	101.82
Weighted-Average Exercise Price, Vested and Exercisable \| $ / shares	$ 160.03

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Expected Volatility, Minimum	90.29%	95.11%
Expected Volatility, Maximum	104.20%	100.34%
Expected Dividends	0.00%	0.00%
Risk Free Interest Rate, Minimum	2.39%	1.81%
Risk Free Interest Rate, Maximum	3.15%	2.66%
Minimum [Member]
Expected Term	5 years 6 months	5 years 4 months 6 days
Maximum [Member]
Expected Term	6 years 6 months 3 days	6 years 6 months 3 days

Net Income (Loss) Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Apr. 30, 2019	Jan. 31, 2019	Apr. 30, 2018	Jan. 31, 2018	Apr. 30, 2019	Apr. 30, 2018
Earnings Per Share [Abstract]
Numerator: Net Income (loss)	$ (9,383)	$ 12,817	$ (13,408)	$ (20,492)	$ 3,434	$ (33,900)
Numerator: Loss attributable to common stockholders – basic and diluted	(9,383)		(13,408)
Numerator: Income (loss) attributable to common stockholders - basic					$ 3,434	$ (33,900)
Numerator: Effect of liability classified warrants					(2,395)
Numerator: Income (loss) attributable to common stockholders - diluted					$ 1,039	$ (33,900)
Denominator: Weighted-average number of common shares used in earnings per share - basic and diluted	5,900,449		3,324,320
Denominator: Weighted-average number of common shares used in earnings per share - basic	5,900,449		3,324,320		5,259,677	3,038,439
Denominator: Effect of dilutive stock options					$ 61
Denominator: Effect of dilutive warrants					23,034
Denominator: Weighted-average number of common shares used in earnings per share - diluted	5,900,449		3,324,320		5,282,772	3,038,439
Loss per share - basic and diluted	$ (1.59)		$ (4.03)
Income (loss) per share - basic	(1.59)		(4.03)		$ 0.65	$ (11.16)
Income (loss) per share - diluted	$ (1.59)		$ (4.03)		$ 0.20	$ (11.16)

Net Income (Loss) Per Share - Schedule of Diluted Weighted-Average Shares Outstanding (Details) - shares	6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Anti Dilutive Securities Total	324,464	588,326
Warrants [Member]
Anti Dilutive Securities Total	72,304	206,160
Stock Options [Member]
Anti Dilutive Securities Total	235,097	309,534
Restricted Stock Units [Member]
Anti Dilutive Securities Total	17,063	72,632

Collaboration and Licensing Agreements (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 08, 2019	Dec. 10, 2018	Aug. 02, 2016	Mar. 19, 2014	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Oct. 31, 2014	Oct. 31, 2018
Number of common stock shares					8,020,370		8,020,370			4,634,189
Cumulative catch-up revenue					$ 1,188	$ 1,747	$ 20,877	$ 3,803
Warrant to purchase shares of common stock					72,304		72,304			944,635
Warrant exercise price per share					$ 3.72		$ 3.72			$ 22.50
Proceeds from issuance of stock							$ 8,982	21,042
Warrants Exercised							(15,300)
Global BioPharma, Inc [Member]
Licensing revenue							$ 250	250
Reimbursement value							2,250
Amgen Agreement [Member] \| Amgen [Member]
Upfront payment			$ 40,000
Number of common stock shares			203,163
Common stock purchase price per share			$ 123.00
Value of stock purchased			$ 25,000
Development, regulatory and sales milestone payments			475,000
Upfront payment recorded as deferred revenue		$ 40,000	$ 40,000
Deferred revenue		18,200
Cumulative catch-up revenue	$ 2,600	$ 15,600			$ 1,200	1,700	20,600	3,600
Reduction in research and development expenses					800	1,600	2,000	3,100
Aratana Agreement [Member] \| Aratana Therapeutics [Member]
Upfront payment				$ 1,000
Common stock purchase price per share				$ 73.50
Development, regulatory and sales milestone payments				$ 36,500
Licensing revenue									$ 1,000
Additional, cumulative sales milestone payments				$ 15,000
Number of common stock shares issued				20,408
Proceeds from royalty received					$ 0	$ 3	$ 2	$ 3
Aratana Agreement [Member] \| Aratana Therapeutics [Member] \| Warrants [Member]
Warrant term				10 years
Warrant to purchase shares of common stock				10,204
Warrant exercise price per share				$ 73.50
Proceeds from issuance of stock				$ 1,500
Warrants Exercised				10,204

Commitments and Contingencies (Details Narrative) - Especificos Stendhal SA de CV [Member] $ in Thousands	Sep. 19, 2018 USD ($)
Damages sought value by plaintiff	$ 3,000
Litigation expense	300
Due from related party	$ 3,000

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		6 Months Ended
	Mar. 29, 2019	Apr. 30, 2019	Feb. 28, 2018	Apr. 30, 2018	Feb. 21, 2019	Oct. 31, 2018
Number of common stock shares sold				58,775
Proceeds from sale of common shares				$ 2,700
Common stock, shares authorized		170,000,000			95,000,000	170,000,000
Reverse stock split, description	1 for 15 reverse stock split
Public Offering [Member]
Number of common stock shares sold		2,500,000	666,667
Proceeds from sale of common shares		$ 9,000	$ 18,400
Sale of stock price per share		$ 4.00	$ 30.00

Stockholders' Equity - Summary of Changes in Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Apr. 30, 2019	Jan. 31, 2019	Apr. 30, 2018	Jan. 31, 2018	Apr. 30, 2019	Apr. 30, 2018
Balance	$ 37,500	$ 24,051	$ 39,263	$ 54,261	$ 24,051	$ 54,261
Stock based compensation	479	622	1,225	2,854
Tax withholdings paid related to net share settlement of equity awards			(33)	(7)
Tax withholdings paid on equity awards	(3)	(11)	(61)	(209)
Tax shares sold to pay for tax withholdings on equity awards	3	11	78	197
Issuance of shares to employees under ESPP Plan	7	9	9
Advaxis at-the-market sales				2,659
Warrant exercises	68
Warrant liability reclassified into equity	53				53
ESPP Expense	1	1
Shares issued in settlement of warrants	5,463
Advaxis public offerings	8,982		18,383
Net Loss	(9,383)	12,817	(13,408)	(20,492)	3,434	(33,900)
Balance	43,170	37,500	45,457	39,263	43,170	45,457
Preferred Stock [Member]
Balance
Balance, shares
Stock based compensation
Stock based compensation, shares
Tax withholdings paid related to net share settlement of equity awards
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
Advaxis at-the-market sales
Advaxis at-the-market sales, shares
Warrant exercises
Warrant exercises, shares
ESPP Expense
Shares issued in settlement of warrants
Shares issued in settlement of warrants, shares
Advaxis public offerings
Advaxis public offerings, shares
Net Loss
Balance
Balance, shares
Common Stock [Member]
Balance	$ 5	$ 5	$ 3	$ 3	$ 5	$ 3
Balance, shares	4,646,007	4,634,189	2,815,975	2,744,196	4,634,189	2,744,196
Stock based compensation
Stock based compensation, shares	693	9,811	17,873	13,003
Tax withholdings paid related to net share settlement of equity awards
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares	1,505	2,007	712
Advaxis at-the-market sales
Advaxis at-the-market sales, shares				58,776
Warrant exercises
Warrant exercises, shares	15,300
ESPP Expense
Shares issued in settlement of warrants	$ 1
Shares issued in settlement of warrants, shares	856,865
Advaxis public offerings	$ 2		$ 1
Advaxis public offerings, shares	2,500,000		666,667
Net Loss
Balance	$ 8	$ 5	$ 4	$ 3	$ 8	$ 4
Balance, shares	8,020,370	4,646,007	3,501,227	2,815,975	8,020,370	3,501,227
Additional Paid-In Capital [Member]
Balance	$ 392,335	$ 391,703	$ 360,894	$ 355,400	$ 391,703	$ 355,400
Stock based compensation	479	622	1,225	2,854
Tax withholdings paid related to net share settlement of equity awards			(33)	(7)
Tax withholdings paid on equity awards	(3)	(11)	(61)	(209)
Tax shares sold to pay for tax withholdings on equity awards	3	11	78	197
Issuance of shares to employees under ESPP Plan	7	9	9
Advaxis at-the-market sales				2,659
Warrant exercises	68
Warrant liability reclassified into equity	53
ESPP Expense	1	1
Shares issued in settlement of warrants	5,462
Advaxis public offerings	8,980		18,382
Net Loss
Balance	407,385	392,335	380,494	360,894	407,385	380,494
Accumulated Deficit [Member]
Balance	(354,840)	(367,657)	(321,634)	(301,142)	(367,657)	(301,142)
Stock based compensation
Tax withholdings paid related to net share settlement of equity awards
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Advaxis at-the-market sales
Warrant exercises
Warrant liability reclassified into equity
ESPP Expense
Shares issued in settlement of warrants
Advaxis public offerings
Net Loss	(9,383)	12,817	(13,407)	(20,492)
Balance	$ (364,223)	$ (354,840)	$ (335,041)	$ (321,634)	$ (364,223)	$ (335,041)

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Apr. 30, 2019	Oct. 31, 2018
Common stock warrant liability, warrants exercisable through September 2024	$ 213	$ 6,517
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable through September 2024
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable through September 2024
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable through September 2024	$ 213	$ 6,517

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	Apr. 30, 2019	Oct. 31, 2018
Fair Value Disclosures [Abstract]
Warrant exercise price per share	$ 3.72	$ 22.50

Fair Value - Schedule of Changes in the Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Apr. 30, 2019	Oct. 31, 2018
Beginning balance	$ 6,517
Change in fair value	200	$ 6,500
Ending Balance	213	6,517
Warrant Liability [Member]
Beginning balance	6,517
Shares issued in settlement of warrants	(3,856)
Warrant exercises	(53)
Change in fair value	2,395
Ending Balance	$ 213	$ 6,517